Classical AD diagnostics rely on the clinical manifestations of the disease supported by brain imaging approaches and blood/cerebrospinal fluid (CSF) biomarker strategies [78] These include the measurement of Aβ1-42/Aβ1-40 ratio, Tau and phosphorylated Tau peptides in the CSF; amyloid and Tau position emission tomography (PET) as direct imaging biomarkers for Aβ and Tau pathology, respectively; and volumetric magnetic resonance imaging (MRI) of the brain as a surrogate of neurodegeneration [79]. This evidence concerns the gene MAPT and Alzheimer disease.